{"id":71402,"date":"2026-07-30T20:44:58","date_gmt":"2026-07-30T12:44:58","guid":{"rendered":"https:\/\/flcube.com\/?p=71402"},"modified":"2026-07-30T20:44:59","modified_gmt":"2026-07-30T12:44:59","slug":"huahai-pharmaceuticals-anti-il-36r-antibody-huayijing-receives-nmpa-priority-review-approval-for-generalized-pustular-psoriasis-flares","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71402","title":{"rendered":"Huahai Pharmaceutical&#8217;s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Zhejiang Huahai Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600521:SHA\">SHA: 600521<\/a>) announced that its <strong>Category 1 therapeutic biologic HB0034 (trade name: Huayijing)<\/strong> has received <strong>marketing approval from China&#8217;s National Medical Products Administration (NMPA)<\/strong> under <strong>priority review designation<\/strong> for the treatment of <strong>generalized pustular psoriasis (GPP) flares in adults weighing \u226540 kg<\/strong>. As <strong>China&#8217;s first domestically developed innovative anti-IL-36R antibody<\/strong>, Huayijing represents a breakthrough therapy for this rare, life-threatening systemic neutrophilic skin disease, demonstrating <strong>rapid and significant pustule clearance within one week<\/strong> of single-dose administration.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing approval under Priority Review<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HB0034 (Huayijing) \u2013 anti-IL-36R monoclonal antibody<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Category 1 innovative therapeutic biologic<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Treatment of generalized pustular psoriasis (GPP) flares in adults \u226540 kg<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First domestically developed anti-IL-36R antibody in China<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-clinical-efficacy\" class=\"wp-block-heading\">Drug Profile &amp; Clinical Efficacy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action:<\/strong> <strong>Anti-IL-36R monoclonal antibody<\/strong> that inhibits the <strong>IL-36 inflammatory pathway<\/strong>, a key driver of neutrophilic inflammation in GPP<\/li>\n\n\n\n<li><strong>Clinical Trial Results:<\/strong><\/li>\n\n\n\n<li><strong>Primary Endpoint Met:<\/strong> Significant clearance of skin pustules by <strong>Week 1<\/strong> compared to placebo<\/li>\n\n\n\n<li><strong>Dosing Regimen:<\/strong> Single intravenous dose demonstrated rapid onset of action<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Favorable safety with <strong>no new safety signals identified<\/strong><\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> <strong>First-in-class domestically developed<\/strong> IL-36 pathway inhibitor in China<\/li>\n\n\n\n<li><strong>Therapeutic Impact:<\/strong> Addresses critical need for <strong>rapid-acting, targeted therapy<\/strong> in acute GPP flares<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-disease-context-amp-market-need\" class=\"wp-block-heading\">Disease Context &amp; Market Need<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Generalized pustular psoriasis (GPP)<\/strong> is an <strong>ultra-rare, life-threatening condition<\/strong> affecting approximately <strong>1-2 per million people globally<\/strong>, with potentially fatal complications including <strong>sepsis, multi-organ failure, and cardiovascular events<\/strong>. Prior to Huayijing&#8217;s approval, treatment options were limited to <strong>off-label systemic immunosuppressants<\/strong> with suboptimal efficacy and significant safety concerns.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>global GPP therapeutics market<\/strong>, while small in patient population, commands <strong>premium pricing<\/strong> due to high unmet need and life-threatening nature of the disease. <strong>Spesolimab<\/strong> (anti-IL-36R antibody) received FDA approval in 2022, validating the IL-36 pathway as a <strong>clinically proven target<\/strong>, but remains unavailable in many markets including China until now.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Key clinical advantages of Huayijing:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rapid onset of action<\/strong> (significant improvement within 7 days)<\/li>\n\n\n\n<li><strong>Targeted mechanism<\/strong> addressing root cause rather than broad immunosuppression<\/li>\n\n\n\n<li><strong>Favorable safety profile<\/strong> suitable for acute flare management<\/li>\n\n\n\n<li><strong>Domestic availability<\/strong> ensuring patient access in China&#8217;s healthcare system<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Huahai Pharmaceutical:<\/strong> Marks transformation from <strong>generic manufacturer to innovative biologics developer<\/strong>, creating new revenue streams beyond traditional business<\/li>\n\n\n\n<li><strong>Market Leadership:<\/strong> Establishes <strong>first-mover advantage<\/strong> in China&#8217;s GPP treatment market with potential for international expansion<\/li>\n\n\n\n<li><strong>Pricing Power:<\/strong> <strong>Orphan drug status<\/strong> and life-threatening indication support premium pricing strategy<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Success validates Huahai&#8217;s <strong>biologics development capabilities<\/strong> and supports advancement of other pipeline candidates<\/li>\n\n\n\n<li><strong>Healthcare Impact:<\/strong> Addresses <strong>critical gap in China&#8217;s rare disease treatment landscape<\/strong>, aligning with national healthcare priorities<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-outlook\" class=\"wp-block-heading\">Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> Estimated <strong>1,000-2,000 GPP patients<\/strong> in China requiring acute flare treatment annually<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Expected to command <strong>annual treatment costs of RMB 300,000-500,000<\/strong> based on international benchmarks<\/li>\n\n\n\n<li><strong>Reimbursement:<\/strong> Likely candidate for <strong>National Reimbursement Drug List (NRDL)<\/strong> inclusion given orphan status and life-threatening indication<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Leveraging Huahai&#8217;s established <strong>biologics manufacturing infrastructure<\/strong> for commercial-scale production<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Potential for <strong>regional partnerships<\/strong> in Asia-Pacific markets with similar unmet needs<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps\" class=\"wp-block-heading\">Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Launch:<\/strong> Immediate market availability through specialized dermatology centers and rare disease networks<\/li>\n\n\n\n<li><strong>Physician Education:<\/strong> Comprehensive training programs for dermatologists and emergency medicine specialists on GPP recognition and treatment<\/li>\n\n\n\n<li><strong>Real-World Evidence:<\/strong> Post-marketing surveillance studies to further validate long-term efficacy and safety<\/li>\n\n\n\n<li><strong>International Filings:<\/strong> Preparation for <strong>regulatory submissions in Southeast Asia and emerging markets<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial launch, market adoption, and international expansion. Actual results may differ due to risks including market acceptance, reimbursement decisions, competitive developments, and regulatory requirements in other jurisdictions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600521_20260730_7W2A.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600521_20260730_7W2A.\"><\/object><a id=\"wp-block-file--media-e07a720a-702b-4759-9be1-26d32e404370\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600521_20260730_7W2A.pdf\">600521_20260730_7W2A<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600521_20260730_7W2A.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e07a720a-702b-4759-9be1-26d32e404370\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that its Category 1 therapeutic biologic HB0034&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[775,15,1381],"class_list":["post-71402","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-huahai-pharmaceutical","tag-product-approvals","tag-sha-600521"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huahai Pharmaceutical&#039;s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that its Category 1 therapeutic biologic HB0034 (trade name: Huayijing) has received marketing approval from China&#039;s National Medical Products Administration (NMPA) under priority review designation for the treatment of generalized pustular psoriasis (GPP) flares in adults weighing \u226540 kg. As China&#039;s first domestically developed innovative anti-IL-36R antibody, Huayijing represents a breakthrough therapy for this rare, life-threatening systemic neutrophilic skin disease, demonstrating rapid and significant pustule clearance within one week of single-dose administration.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71402\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huahai Pharmaceutical&#039;s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares\" \/>\n<meta property=\"og:description\" content=\"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that its Category 1 therapeutic biologic HB0034 (trade name: Huayijing) has received marketing approval from China&#039;s National Medical Products Administration (NMPA) under priority review designation for the treatment of generalized pustular psoriasis (GPP) flares in adults weighing \u226540 kg. As China&#039;s first domestically developed innovative anti-IL-36R antibody, Huayijing represents a breakthrough therapy for this rare, life-threatening systemic neutrophilic skin disease, demonstrating rapid and significant pustule clearance within one week of single-dose administration.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71402\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T12:44:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-30T12:44:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71402#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71402\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huahai Pharmaceutical&#8217;s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares\",\"datePublished\":\"2026-07-30T12:44:58+00:00\",\"dateModified\":\"2026-07-30T12:44:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71402\"},\"wordCount\":628,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Huahai Pharmaceutical\",\"Product approvals\",\"SHA: 600521\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71402#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71402\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71402\",\"name\":\"Huahai Pharmaceutical's Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-30T12:44:58+00:00\",\"dateModified\":\"2026-07-30T12:44:59+00:00\",\"description\":\"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that its Category 1 therapeutic biologic HB0034 (trade name: Huayijing) has received marketing approval from China's National Medical Products Administration (NMPA) under priority review designation for the treatment of generalized pustular psoriasis (GPP) flares in adults weighing \u226540 kg. As China's first domestically developed innovative anti-IL-36R antibody, Huayijing represents a breakthrough therapy for this rare, life-threatening systemic neutrophilic skin disease, demonstrating rapid and significant pustule clearance within one week of single-dose administration.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71402#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71402\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71402#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huahai Pharmaceutical&#8217;s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huahai Pharmaceutical's Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares - Insight, China&#039;s Pharmaceutical Industry","description":"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that its Category 1 therapeutic biologic HB0034 (trade name: Huayijing) has received marketing approval from China's National Medical Products Administration (NMPA) under priority review designation for the treatment of generalized pustular psoriasis (GPP) flares in adults weighing \u226540 kg. As China's first domestically developed innovative anti-IL-36R antibody, Huayijing represents a breakthrough therapy for this rare, life-threatening systemic neutrophilic skin disease, demonstrating rapid and significant pustule clearance within one week of single-dose administration.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71402","og_locale":"en_US","og_type":"article","og_title":"Huahai Pharmaceutical's Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares","og_description":"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that its Category 1 therapeutic biologic HB0034 (trade name: Huayijing) has received marketing approval from China's National Medical Products Administration (NMPA) under priority review designation for the treatment of generalized pustular psoriasis (GPP) flares in adults weighing \u226540 kg. As China's first domestically developed innovative anti-IL-36R antibody, Huayijing represents a breakthrough therapy for this rare, life-threatening systemic neutrophilic skin disease, demonstrating rapid and significant pustule clearance within one week of single-dose administration.","og_url":"https:\/\/flcube.com\/?p=71402","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-30T12:44:58+00:00","article_modified_time":"2026-07-30T12:44:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71402#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71402"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huahai Pharmaceutical&#8217;s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares","datePublished":"2026-07-30T12:44:58+00:00","dateModified":"2026-07-30T12:44:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71402"},"wordCount":628,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Huahai Pharmaceutical","Product approvals","SHA: 600521"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71402#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71402","url":"https:\/\/flcube.com\/?p=71402","name":"Huahai Pharmaceutical's Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-30T12:44:58+00:00","dateModified":"2026-07-30T12:44:59+00:00","description":"Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that its Category 1 therapeutic biologic HB0034 (trade name: Huayijing) has received marketing approval from China's National Medical Products Administration (NMPA) under priority review designation for the treatment of generalized pustular psoriasis (GPP) flares in adults weighing \u226540 kg. As China's first domestically developed innovative anti-IL-36R antibody, Huayijing represents a breakthrough therapy for this rare, life-threatening systemic neutrophilic skin disease, demonstrating rapid and significant pustule clearance within one week of single-dose administration.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71402#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71402"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71402#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huahai Pharmaceutical&#8217;s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71402"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71402\/revisions"}],"predecessor-version":[{"id":71404,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71402\/revisions\/71404"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}